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Dominant Mutations in GRM1
Cause Spinocerebellar Ataxia Type 44
Lauren M. Watson,1 Elizabeth Bamber,1 Ricardo Parolin Schnekenberg,2 Jonathan Williams,3
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The metabotropic glutamate receptor 1 (mGluR1) is abundantly expressed in the mammalian central nervous system, where it regulates
intracellular calcium homeostasis in response to excitatory signaling. Here, we describe heterozygous dominant mutations in GRM1,
which encodes mGluR1, that are associated with distinct disease phenotypes: gain-of-function missense mutations, linked in two
different families to adult-onset cerebellar ataxia, and a de novo truncation mutation resulting in a dominant-negative effect that is
associated with juvenile-onset ataxia and intellectual disability. Crucially, the gain-of-function mutations could be pharmacologically
modulated in vitro using an existing FDA-approved drug, Nitazoxanide, suggesting a possible avenue for treatment, which is currently
unavailable for ataxias.Glutamate is the most abundant excitatory neurotrans-
mitter in the mammalian brain.1 Postsynaptic glutamate
signaling is mediated by two classes of receptors: iono-
tropic glutamate receptors (iGluRs), which mediate rapid
synaptic transmission; and metabotropic glutamate recep-
tors (mGluRs), which are coupled to G proteins and
produce a more complex postsynaptic response consisting
of both internal calcium release and a slow excitatory
postsynaptic potential. mGluR1, encoded by GRM1
(MIM: 604473), is one of the most abundant mGluRs in
the mammalian central nervous system and is present at
particularly high levels in Purkinje cells, the primary neu-
rons of the cerebellar cortex. Multiple lines of evidence
have implicated mGluR1 as a central player in diseases
involving glutamatergic dysfunction and abnormal synap-
tic plasticity.2,3 Nevertheless, disease-causing mutations
within GRM1 itself appear remarkably rare.4 The only
GRM1mutations identified to date have been found either
to cause an autosomal-recessive spinocerebellar ataxia
(SCAR13 [MIM: 614831]) in a small Roma cohort with a
known founder effect5 or to associate with autosomal-
recessive intellectual disability in a single consanguineous
Iranian family.6
Here, we report heterozygous dominant mutations in
GRM1 associated with two distinct phenotypes. Missense
mutations in GRM1 were identified in two different fam-
ilies with an adult-onset degenerative disorder primarily
causing cerebellar ataxia with some cortical involvement
causing spasticity: c.2375A>G (p.Tyr792Cys) in family 1
and c.785A>G (p.Tyr262Cys) in family 2 (Figures 1A and
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20 and 50 years (see Supplemental Note). There was no
evidence of cognitive impairment, but in family 1, individ-
ual III:1 has evidence of corticospinal tract involvement
with a narrow stiff gait and brisk reflexes. Brain MRI
in members of both families revealed cerebellar atrophy,
with mild flattening of the pons in family 1. Genetic
testing for spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7, and
17 (MIM: 164400, 183090, 109150, 183086, 164500,
and 607136) did not detect any mutations. We also identi-
fied a heterozygous base pair duplication in GRM1 in
another individual (c.3165dup [p.Gly1056Argfs*49]). In
family 3 the parents are unaffected, but the child has
intellectual disability and cerebellar ataxia without
apparent cerebellar atrophy, and normal brain imaging
(Figure 1A).
Consent for participation in the study was obtained ac-
cording to the Declaration of Helsinki (WMA, 1997) and
approved by the Central Oxford Research Ethics Commit-
tee and the Research and Development Department of the
Oxford Radcliffe Hospitals NHS Trust (approval number
C03.052), Oxford. Work at University College London
Hospitals was conducted under UCLH Project ID Number:
08/0512/26. All participating individuals or their parents
provided written consent for the study.
Variants of interest in GRM1 were identified by means of
whole-exome (families 1 and 2) or targeted (family 3)
sequencing, with results verified by Sanger sequencing.
In the case of family 1, Covaris shearing of DNA was fol-
lowed by library preparation using the Agilent SureSelect
Exome V5 probe kit and SureSelectXT target enrichmentord OX1 3PT, UK; 2Nuffield Department of Clinical Neurosciences, Univer-
U, UK; 3Oxford Medical Genetics Laboratories, Churchill Hospital, Oxford
University College London, LondonWC1N 3BG, UK; 5Department of Clin-
on, LondonWC1N 3BG, UK; 6West Midlands Regional Genetics Laboratory,
15 2TG, UK; 7MRC Computational Genomics Analysis and Training Pro-
ford, John Radcliffe Hospital, Oxford OX3 9DS, UK; 8Oxford Centre for
, UK
cn.ox.ac.uk (A.H.N.)
Journal of Human Genetics 101, 451–458, September 7, 2017 451
(http://creativecommons.org/licenses/by/4.0/).
Figure 1. Dominant Mutations in GRM1 Result in a Cerebellar
Phenotype
(A) MRI brain imaging of case subjects. Top left: family 1, affected
son (II:1); top right: family 1, affected granddaughter (III:1), both
showing cerebellar atrophy. Bottom left: family 2, affected brother
(II:1) showing cerebellar atrophy; bottom right: family 3, affected
daughter (II:1), showing normal imaging. The cerebellum is indi-
cated in each case by an arrow.
(B) Pedigrees of affected families. Squares denote male family
members, circles female family members, and black symbols
affected family members. Probands are indicated in each case by
an arrow. The following individuals were sequenced: family 1
I:2, II:1, and III:1; family 2 II:1, II:2, and III:1; family 3 I:1, I:2,
and II:1. Asterisks (*) indicate the presence of the mutation.
452 The American Journal of Human Genetics 101, 451–458, Septemchemistry. The prepared libraries were sequenced by 23
100-bp paired end sequencing on a HiSeq2500 in rapid
run mode. A minimum of 98.37% of the on-target regions
were covered to a depth of at least 203. The exome data
were processed using an in-house bioinformatic pipeline
as previously described.7
For family 2, whole-exome sequencing (WES) was per-
formed in the three family members. The TruSeq Exome
Enrichment (62 Mb) or the Nextera Rapid Capture Exome
(37 Mb) Enrichment kits (Illumina) were used according to
the manufacturer instructions. Libraries were sequenced
using an Illumina HiSeq2500 using a 100-bp paired-end
reads protocol. In the proband, a minimum of 94.66% of
the on-target regions were covered to a depth of at least
103. Sequence alignment to the human reference genome
(UCSC hg19) and variants call and annotation were per-
formed using an in-house pipeline as described else-
where.8 The raw list of single-nucleotide variants (SNVs)
and indels was then filtered. Only exonic and donor/
acceptor splicing variants were considered. Priority was
given to rare variants (<1% in public databases, including
1000 Genomes project, NHLBI Exome Variant Server,
Complete Genomics 69, and Exome Aggregation Con-
sortium [ExAC v0.2] with a GERPþþ score above 2).
Synonymous variants were not considered nor were vari-
ants present in our in-house exome database in pheno-
types other than ataxia.
For family 3, targeted sequencing of 92 ataxia-associated
genes (see Table S1) was performed in the proband using a
custom design Haloplex enrichment kit (Agilent Technolo-
gies) on the Ilumina MiSeq platform. Data analysis was
performed using an in-house pipeline. Identified variants
were filtered against in-house lists of known sequencing
artifacts and polymorphisms and of variants found in the
Exome Variant Server dataset at a minor allele frequency
of 1% or greater. Horizontal coverage of the target genes
at a read-depth of 303 is included in Table S1. The variant
was confirmed as having arisen de novo by Sanger
sequencing of parental DNA, and familial relationships
were confirmed using the AmpFLSTR Identifiler Plus PCR
amplification kit (ThermoFisher Scientific).
Both the heterozygous c.2375A>G (p.Tyr792Cys) (fam-
ily 1) and c.785A>G (p.Tyr262Cys) (family 2) missense
variants were predicted to be pathogenic by standard
bioinformatics pathogenicity programs (Table 1). The het-
erozygous c.3165dup (p.Gly1056Argfs*49) variant identi-
fied in the proband of family 3 occurs in the final GRM1(C) Schematic representation of the positions of the dominant
mutations withinmGluR1. At the N terminus, the amino-terminal
domain (ATD) is followed by the cysteine-rich domain (CRD),
seven transmembrane domains (TMD), and the intracellular
C-terminal domain (CTD). Cysteine residues, which function in
dimerization, are indicated by S. GRM1 mutations are indicated
by black stars. The p.Tyr262Cys variant is located in the extra-
cellular ligand-binding region, p.Tyr792Cys within transmem-
brane helix 6, and p.Gly1056Argfs*49 in the C-terminal domain
of the receptor. Figure adapted from Willard and Koochekpour.42
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Table 1. Summary of GRM1 Variants Identified by Sequencing in Affected Families
Family 1 Family 2 Family 3
Genome reference GRCh37:g.146720550A>G GRCh37:g.146480568A>G GRCh37:g.146755512dup
Transcript NM_001278064.1 NM_001278064.1 NM_001278064.1
Nucleotide c.2375A>G c.785A>G c.3165dup
Protein p.Tyr792Cys p.Tyr262Cys p.Gly1056Argfs*49
PhyloP 5.05 [-14.1;6.4] 4.56 [-14.1;6.4] not applicable
Grantham 194 [0-215] 194 [0-215] not applicable
PolyPhen 0.999 (probably damaging) 0.999 (probably damaging) not applicable
Align GVGD C65 (GV:0.00 - GD:193.72) C0 (GV:353.86 - GD:0.00) not applicable
SIFT score: 0, median: 4.32 score: 0, median: 4.32 not applicable
Mutation Taster disease causing (p value: 1) disease causing (p value: 1) not applicable
ExAc absent absent absentexon, and as such is not predicted to be subject to
nonsense-mediated decay (NMD) but rather to result in
the production of a truncated protein. The presence of
protein levels for all three variants was confirmed
following transient overexpression in HEK293FT cells
(Figures 2A and 2C), although further confirmation of
p.Gly1056Argfs*49 mGluR1 levels in primary cells would
be necessary to conclusively rule out the possibility of
NMD.
Publicly available gene and protein expression data
(Allen Mouse Brain Atlas and Human Brain Transcriptome
Project) show particularly high levels of mGluR1 in the
Purkinje cells of the cerebellar cortex, where its signaling
is critically important for memory formation, motor
learning, and co-ordination.9 Activation of mGluR1 in
response to glutamatergic signaling at Purkinje cell excit-
atory synapses triggers a complex pathway involving
inositol triphosphate receptor-dependent release of intra-
cellular calcium. The correct function of mGluR1 in these
signaling cascades is facilitated by a number of interaction
partners, including the scaffold protein Homer2b.10 Bind-
ing of the intracellular C-terminal domain of group I
mGluRs to Homer2b results in recruitment and clustering
of both proteins at the plasma membrane11 and con-
tributes to the organization of efficient signaling do-
mains.12,13 To assess the effect of the identified GRM1
mutations on this clustering, HEK293FT cells were tran-
siently co-transfected with mGluR1 and Homer2b fol-
lowed by immunostaining. For each GRM1 mutation,
100 cells co-expressing FLAG-tagged mGluR1 and Hom-
er2b were counted, and the distribution of mGluR1 was
classified as either ‘‘clustered’’ or ‘‘diffuse’’ based on the
presence or absence of punctate staining in each cell.
Representative images of this clustering are shown in
Figure 2A. For further verification, immunostaining of cells
using an anti-FLAG antibody was compared with immuno-
staining using an antibody against the N terminus of
mGluR1 (Figure S1). Expression of the truncation muta-The Americantion (p.Gly1056Argfs*49) resulted in complete ablation
of mGluR1-Homer2b clustering (Figures 2A and 2B). By
contrast, the missense mutations (p.Tyr262Cys and
p.Tyr792Cys) showed similar clustering patterns to wild-
type (WT) mGluR1, indicating that neither of these
mutations affects the clustering with Homer2b. Of note,
overexpression of p.Gly1056Argfs*49 mGluR1 was also
associated with decreased levels of phosphorylated
ERK1/2, a downstream target of activated mGluR1,14
when compared to WT-mGluR1 or either of the point mu-
tations (Figure 2C).
To evaluate the effects of each mutation on mGluR1
receptor activity, we employed a luciferase assay based on
mGluR1-induced transcriptional activation following
arrestin translocation (Tango), as previously described
(Figure 3A).15 Consistent with the results of the immuno-
staining and biochemical experiments, p.Gly1056Argfs*
49 mGluR1 showed dramatically reduced receptor activity
relative toWT (p < 0.01) (Figure 3C). Taken together, these
results suggest that the truncating mGluR1 mutation
causes a dominant-negative effect, resulting in a loss of
receptor function and consequent disruption of down-
stream signaling events.
By contrast, both missense mutations resulted in
significantly enhanced receptor activity compared to WT
(p < 0.0001) (Figure 3C), suggesting a gain-of-function
mechanism. To determine whether this effect was due
to enhanced ligand sensitivity or a result of ligand-indepen-
dent activation,mGluR1-transfected cells were treatedwith
either a competitive (MCPG) or a non-competitive (BAY36-
7620) antagonist of mGluR1. Treatment with either antag-
onist partially reduced the activity of p.Tyr262Cys and
p.Tyr792Cys mGluR1 (p < 0.0001). However, a combina-
tion of both antagonists was required to reduce mutant
and WT receptor activity to similar levels (Figure 3C), sug-
gesting a role for both ligand-dependent and -independent
mechanisms in the enhanced activity resulting from these
mutations. These results are in keeping with the molecularJournal of Human Genetics 101, 451–458, September 7, 2017 453
Figure 2. Deletion of the C-Terminal
Domain of mGluR1 Affects Binding to
Homer2b
GRM1 expression constructs were gener-
ated using GRM1-Tango (Addgene plasmid
66387),15 into which a stop codon was in-
serted to prevent readthrough into the
Tango element. The three dominant muta-
tions were introduced by site-directed
mutagenesis, and results were verified by
Sanger sequencing. Constructs were trans-
fected into HEK293FT cells (Invitrogen),
using Lipofectamine 3000 (Thermo Fisher
Scientific). 24 hr after transfection, cells
were subjected to immunostaining using
the following primary antibodies: mouse
anti-FLAG (1:500; Sigma-Aldrich), rabbit
anti-MYC (1:500; Abcam), and goat anti-
mGluR1 (1:500; Santa-Cruz). Secondary
antibodies: goat anti-mouse Alexa594 or
Alexa488, goat anti-rabbit Alexa488, and
donkey anti-goat Alexa594 (all 1:1,000;
Life Technologies). Nuclei were stained
with DAPI.
(A) Cells transfected with FLAG-tagged
mGluR1 only (left) show diffuse localiza-
tion of wild-type (WT) and mutant
mGluR1 (red). Co-transfection with
MYC-tagged Homer2b results in clustering
of WT mGluR1 and the p.Tyr262Cys and
p.Tyr792Cys mutants but not the
p.Gly1056Argfs*49 deletion mutant. Scale
bar: 20 mm.
(B) Quantitative analysis of mGluR1-Hom-
er2b clustering. For each biological repli-
cate, 100 cells were counted. Bars show
the mean of three biological replicates 5
SEM. ***p < 0.001 (one-way ANOVA, fol-
lowed by Bonferroni’s multiple compari-
son test).
(C) Western blot analysis of mGluR1 and
components of its downstream signaling
cascade. Protein extracts were prepared
from cultured cells 24 hr after transfection, in ice-cold RIPA buffer (Thermo Fisher) containing 13 cOmplete, Mini, EDTA-free Protease
Inhibitor Cocktail (Roche), 13 PhosSTOP (Roche), and 1 mM dithiothreitol (DTT), and analyzed by standard SDS-polyacrylamide gel
electrophoresis and immunoblotting. Primary antibodies: rabbit anti-mGluR1 (1:200; Alomone Labs), rabbit anti-p44/42 MAPK
(Erk1/2) and rabbit anti-phospho-p44/42MAPK (Erk1/2) (both 1:1,000; Cell Signaling Technologies), andmouse anti-actin (1:1,000; Ab-
cam). HRP-conjugated secondary antibodies: donkey anti-rabbit and sheep anti-mouse (both 1:10,000; GE Healthcare). A decrease in
phosphorylation of Extracellular Signal-Related Kinase 1/2 (ERK1/2) was observed in cells transfected with the mGluR1
p.Gly1056Argfs*49 mutant, indicating disruption of mGluR1 downstream signaling events.genetics results and in silico pathogenicity predictions.
Both missense mutations are located near regions res-
ponsible for the regulation of mGluR1 activation in
response to glutamate signaling—p.Tyr262Cys in the
ligand-binding domain and p.Tyr792Cys in helix VI of
the transmembrane domain.16,17 Structural analysis of
mGluR1 has revealed a putative role of p.Tyr262Cys in sta-
bilization of the open-open conformation; hence, it is
possible that substitution at this position results in an in-
crease in receptors in the active conformation.16 The
same structural analysis has shown that helix VI undergoes
a substantial conformational change during receptor acti-
vation, a process that may be disrupted by the p.Tyr792Cys
substitution. As further evidence for the importance of this
region, the nearby Trp798 residue has been shown to be454 The American Journal of Human Genetics 101, 451–458, Septemdirectly involved in binding of an allosteric regulator of
mGluR1 activity.16
Mutations that result in excessive mGluR1 signaling
have been hypothesized to result in excitotoxicity via a
positive-feedback mechanism, in which elevated intracel-
lular calcium potentiates mGluR1-mediated signals.18,19
Cerebellar Purkinje cells in particular appear acutely
sensitive to these fluctuations in calcium levels, which
may explain the link between gain of mGluR1 function
and the development of cerebellar ataxia.2 Interestingly,
mutations in genes encoding proteins in the mGluR1
signaling pathway, that result in activation of this
pathway, have been linked to ataxia in several cases,
including the Moonwalker ataxic mouse model20 and the
late-onset, dominantly inherited human diseases SCA1ber 7, 2017
Figure 3. GRM1 Mutations Affect Receptor Activity and Can Be
Pharmacologically Modulated In Vitro
(A) Overview of the modified luciferase reporter assay used
to assess mGluR1 activity. The GRM1-Tango construct, into
which mutations were introduced, consists of a FLAG-tagged
GRM1 sequence followed by the Tango element, i.e., a V2 tail
capable of recruiting b-arrestin, a cleavage site for the tobacco
etch virus (TEV) protease, and a tetracycline-controlled transac-
tivator (tTA). GRM1 mutations are indicated by black stars.
Signaling via mGluR1 results in a conformational change in
the V2 tail and recruitment of b-arrestin, followed by TEV
protease-mediated cleavage and release of tTA, which translo-
cates to the nucleus and activates transcription of the luciferase
reporter gene, resulting in a quantifiable output of mGluR1 ac-
The American(MIM: 164400),21 SCA2 (MIM: 183090),22 SCA28 (MIM:
610246),23 and SCA41 (MIM: 616410),24 which share com-
mon clinical features with the individuals carrying GRM1
missense mutations in the present study.
The de novo p.Gly1056Argfs*49 variant, on the other
hand, produces a truncated form of mGluR1 lacking the
C-terminal domain. This region of the protein, containing
the crucial Homer binding motif, plays an important role
in receptor targeting and the regulation of signal transduc-
tion.25 Hence, it seems likely that deletion of the Homer
binding domain would result in a loss of receptor function,
and given the requirement for dimerization of themGluR1
receptor,26 non-functional monomers likely exert a domi-
nant-negative effect, accounting for the manifestation of
disease in the heterozygous state.
The consequences of a loss of mGluR1 function are
emphasized by results from knockout models, which
show a range of developmental and functional deficits,
both in the cerebellum (impaired long-term depression,
movement ataxia, abnormal innervations of Purkinje
cells, and compensatory mGluR5-mediated excitotoxic-
ity)27–29 and in other brain regions, including impaired
long-term potentiation in the hippocampus and disrup-
tion of pre-pulse inhibition.30,31 This is further supported
by recent reports of altered mGluR1 levels during neuro-
development, in the hippocampus of a rat model of
schizophrenia, highlighting the critical role of glutamate
receptors across several brain regions.32 In humans too,
mutations resulting in a loss of glutamate signaling are
typically associated with a more severe neurodevelopmen-
tal phenotype. For example, individuals carrying the
likely loss-of-function mutations in GRM1 reported bytivity in the form of luminescence (figure adapted from Kroeze
et al.15).
(B) Structure of the mGluR1 endogenous ligand, L-glutamate, and
the inhibitors used in this study: competitive inhibitor MCPG, in-
verse agonist BAY36-7620, and the FDA-approved negative allo-
steric modulator Nitazoxanide.
(C) Relative activity of mGluR1 mutants. HTLA cells, stably ex-
pressing a b-arrestin/TEV protease complex and a tTA-dependent
luciferase reporter gene, were seeded at 70,000 cells/well onto
poly-L-lysine-coated 96-well plates in DMEMwithout L-glutamine
(Life Technologies), containing penicillin, streptomycin, hygrom-
ycin B, and puromycin. After 24 hr, cells were transiently trans-
fected with the four GRM1-Tango constructs (WT, p.Tyr262Cys,
p.Tyr792Cys, and p.Gly1056Argfs*49) and incubated for a further
24 hr. Cells were then treated overnight with 500 mM (RS)-MPCG
(Tocris), 10 mM BAY36-7620 (Tocris), or 10 mM Nitazoxanide
(Sigma-Aldrich), diluted in assay buffer (20 mM HBSS, 13 HEPES
[pH 7.4], both Life Technologies), before cell lysis in Bright-Glo
solution (Promega) and luminescence reading. Data were analyzed
statistically in GraphPad Prism using a two-way analysis of vari-
ance (ANOVA), followed by Bonferroni’s multiple comparison
post hoc test. Significance was defined as p < 0.05 and is shown
here relative tomGluR1wild-type (WT) in the untreated condition
and relative to the corresponding untreated sample for all other
treatment conditions, unless otherwise indicated. Data shown
are mean 5 SEM from one experiment, representative of results
recorded in four biological replicates, each consisting of
three technical replicates per construct per condition. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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Guergueltcheva et al.5 and Davarniya et al.6 or null
mutations in the ionotropic glutamate receptor gene
GRID2 (MIM: 602368)33–37 all showed evidence of devel-
opmental delay and intellectual deficit in addition to
cerebellar ataxia, similar to the individual carrying a
de novo GRM1 nonsense frameshift mutation described
here, albeit to a larger extent. Moreover, epilepsy was
described in one of the reported families with recessive
inheritance5 and spasticity was described in one indi-
vidual5 as well as in a spontaneous recessive Grm1 mouse
mutant.38 Interestingly, spasticity was also observed in
one individual (family 1, III:1) reported here. Together,
these phenotypes are suggestive of cortical dysfunction
and point toward a critical role for mGluR1 in the devel-
opment and function of additional brain regions beyond
the cerebellum.
Pharmacological modulation of mGluR1 activity is at-
tracting increasing attention as a promising therapeutic
approach for the treatment of cerebellar ataxia.3 Indeed,
negative modulators of mGluR1 activity have already
been used with some success in the treatment of ataxia
symptoms in mouse models.21,39 In an attempt to identify
a readily available potential therapeutic compound, we
selected Nitazoxanide, an FDA-approved drug, that was
identified in a recent in silico-in vivo repositioning study
as a negative allosteric modulator of mGluR1/540 and
examined its ability to rescue the excessive mGluR1
signaling caused by the p.Tyr262Cys and p.Tyr792Cys
missense variants in vitro. Treatment with a single 10 mM
dose of Nitazoxanide proved to be a potent inhibitor of
both of these mutant forms of mGluR1 in transiently
transfected HEK293FT cells, as assessed by the Tango
luciferase assay (Figure 3C). Given the structural similarity
of its active metabolite tizoxanide to the inverse agonist
BAY36-7620,40 it is likely that Nitazoxanide functions in
a similar manner, decreasing the maximal effect of gluta-
mate on mGluR1, regardless of the mechanism of action
of the mutations.41 As treatment with Nitazoxanide also
results in inhibition of WT receptor activity, however,
in vivo drug titration will be required to assess therapeutic
efficacy. Nonetheless, these results suggest a viable thera-
peutic strategy using mGlur1 inhibitors for individuals
with gain-of-function mutations in GRM1.
In summary, we report that dominant mutations in
GRM1 cause spinocerebellar ataxia type 44 (SCA44). Our
study not only emphasizes the central role of mGluR1-
mediated signaling in cerebellar function, but also pro-
vides valuable insights into genotype-phenotype correla-
tions beyond ataxia. The finding that drugs modulate
mGluR1-mediated signaling in the presence of human
mutations warrants further exploration of possible thera-
peutic avenues involving mGluR1 pathways.Accession Numbers
The accession number for the spinocerebellar ataxia type 44
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